GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » EV-to-EBIT

OBI Pharma (ROCO:4174) EV-to-EBIT : -6.59 (As of Sep. 25, 2024)


View and export this data going back to 2015. Start your Free Trial

What is OBI Pharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, OBI Pharma's Enterprise Value is NT$15,352.09 Mil. OBI Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-2,330.81 Mil. Therefore, OBI Pharma's EV-to-EBIT for today is -6.59.

The historical rank and industry rank for OBI Pharma's EV-to-EBIT or its related term are showing as below:

ROCO:4174' s EV-to-EBIT Range Over the Past 10 Years
Min: -100.37   Med: -14.02   Max: -5.78
Current: -6.58

During the past 13 years, the highest EV-to-EBIT of OBI Pharma was -5.78. The lowest was -100.37. And the median was -14.02.

ROCO:4174's EV-to-EBIT is ranked worse than
100% of 440 companies
in the Biotechnology industry
Industry Median: 8.655 vs ROCO:4174: -6.58

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. OBI Pharma's Enterprise Value for the quarter that ended in Jun. 2024 was NT$13,687.24 Mil. OBI Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-2,330.81 Mil. OBI Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -17.03%.


OBI Pharma EV-to-EBIT Historical Data

The historical data trend for OBI Pharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OBI Pharma EV-to-EBIT Chart

OBI Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.00 -16.64 -12.35 -6.68 -11.66

OBI Pharma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.65 -12.40 -11.66 -9.61 -5.87

Competitive Comparison of OBI Pharma's EV-to-EBIT

For the Biotechnology subindustry, OBI Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OBI Pharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OBI Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where OBI Pharma's EV-to-EBIT falls into.



OBI Pharma EV-to-EBIT Calculation

OBI Pharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=15352.086/-2330.81
=-6.59

OBI Pharma's current Enterprise Value is NT$15,352.09 Mil.
OBI Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-2,330.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OBI Pharma  (ROCO:4174) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

OBI Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 ) =EBIT / Enterprise Value (Q: Jun. 2024 )
=-2330.81/13687.2414
=-17.03 %

OBI Pharma's Enterprise Value for the quarter that ended in Jun. 2024 was NT$13,687.24 Mil.
OBI Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-2,330.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OBI Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of OBI Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


OBI Pharma Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Park Street, Room. 1907, 19th Floor, Nangang District, Taipei, TWN, 115
OBI Pharma Inc is part of the healthcare sector. The company and its subsidiaries are engaged in new drug research. Its focus is on the unmet medical need in challenging diseases throughout the world, such as cancer. OBI strives to improve health and the quality of life through cost-effective therapeutics. The Group has four reportable segments, which are the anti-cancer new drug segment, bispecific monoclonal antibody new drug segment, botulinum toxin new drug segment, and CDMO segment.

OBI Pharma Headlines

No Headlines